269 related articles for article (PubMed ID: 29661179)
21. Impact of tumor size on patient survival after radical nephrectomy for pathological T3a renal cell carcinoma.
Sugiyama Y; Yatsuda J; Murakami Y; Ito N; Yamasaki T; Mikami Y; Ogawa O; Kamba T
Jpn J Clin Oncol; 2019 May; 49(5):465-472. PubMed ID: 30793163
[TBL] [Abstract][Full Text] [Related]
22. Hilar location is an independent prognostic factor for recurrence in T1 renal cell carcinoma after nephrectomy.
Shim M; Song C; Park S; Kim A; Choi SK; Kim CS; Ahn H
Ann Surg Oncol; 2015 Jan; 22(1):344-50. PubMed ID: 25323469
[TBL] [Abstract][Full Text] [Related]
23. Survival Analysis of Pathological T3a Upstaging in Clinical T1 Renal Cell Carcinoma.
Lai GS; Li JR; Wang SS; Chen CS; Yang CK; Hung SC; Cheng CL; Ou YC; Chiu KY
In Vivo; 2020; 34(2):799-805. PubMed ID: 32111787
[TBL] [Abstract][Full Text] [Related]
24. Predictive factors for late recurrence in patients with stage T1 clear cell renal cell carcinoma: a multiinstitutional study.
Ha YS; Park YH; Kang SH; Hong SH; Hwang TK; Byun SS; Kim YJ
Clin Genitourin Cancer; 2013 Mar; 11(1):51-5. PubMed ID: 23017336
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of the prognostic significance of perirenal fat invasion and tumor size in patients with pT1-pT3a localized renal cell carcinoma in a comprehensive multicenter study of the CORONA project. Can we improve prognostic discrimination for patients with stage pT3a tumors?
Brookman-May SD; May M; Wolff I; Zigeuner R; Hutterer GC; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Tubaro A; Coman I; Truss M; Dalpiaz O; Feciche B; Figenshau RS; Madison K; Sánchez-Chapado M; Santiago Martin Mdel C; Salzano L; Lotrecchiano G; Zastrow S; Wirth M; Sountoulides P; Shariat S; Waidelich R; Stief C; Gunia S; ;
Eur Urol; 2015 May; 67(5):943-51. PubMed ID: 25684695
[TBL] [Abstract][Full Text] [Related]
26. Renal cell carcinoma: evaluation of the 1997 TNM system and recommendations for follow-up after surgery.
Gofrit ON; Shapiro A; Kovalski N; Landau EH; Shenfeld OZ; Pode D
Eur Urol; 2001 Jun; 39(6):669-74; discussion 675. PubMed ID: 11464056
[TBL] [Abstract][Full Text] [Related]
27. Adverse pathologic features impact survival outcomes for small renal masses following nephrectomy.
Khaleel S; Truong H; Jiang S; K-Lee P; Davelman B; Gordon D; Benfante N; Arora A; Ostrovnaya I; Tickoo S; Coleman J; Hakimi AA; Russo P
Urol Oncol; 2023 Sep; 41(9):391.e5-391.e11. PubMed ID: 37423816
[TBL] [Abstract][Full Text] [Related]
28. Pathological Stage T3a Significantly Increases Disease Recurrence across All Tumor Sizes in Renal Cell Carcinoma.
Chevinsky M; Imnadze M; Sankin A; Winer A; Mano R; Jakubowski C; Mashni J; Sjoberg DD; Chen YB; Tickoo SK; Reuter VE; Hakimi AA; Russo P
J Urol; 2015 Aug; 194(2):310-5. PubMed ID: 25676433
[TBL] [Abstract][Full Text] [Related]
29. The critical impact of tumor size in predicting cancer special survival for T3aM0M0 renal cell carcinoma: A proposal of an alternative T3aN0M0 stage.
Li L; Shi L; Zhang J; Fan Y; Li Q
Cancer Med; 2021 Jan; 10(2):605-614. PubMed ID: 33280246
[TBL] [Abstract][Full Text] [Related]
30. Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy.
Itano NB; Blute ML; Spotts B; Zincke H
J Urol; 2000 Aug; 164(2):322-5. PubMed ID: 10893575
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of nephron-sparing surgery for renal cell carcinoma: analysis based on the new 1997 tumor-node-metastasis staging system.
Belldegrun A; Tsui KH; deKernion JB; Smith RB
J Clin Oncol; 1999 Sep; 17(9):2868-75. PubMed ID: 10561364
[TBL] [Abstract][Full Text] [Related]
32. Can partial nephrectomy provide equal oncological efficiency and safety compared with radical nephrectomy in patients with renal cell carcinoma (≥4cm)? A propensity score-matched study.
Lee H; Oh JJ; Byun SS; Jeong CW; Kwak C; Jeong BC; Jeon SS; Lee HM; Choi HY; Seo SI
Urol Oncol; 2017 Jun; 35(6):379-385. PubMed ID: 28284894
[TBL] [Abstract][Full Text] [Related]
33. Management and extended outcome of patients with synchronous bilateral solid renal neoplasms in the absence of von Hippel-Lindau disease.
Blute ML; Amling CL; Bryant SC; Zincke H
Mayo Clin Proc; 2000 Oct; 75(10):1020-6. PubMed ID: 11040850
[TBL] [Abstract][Full Text] [Related]
34. The key role of time in predicting progression-free survival in patients with renal cell carcinoma treated with partial or radical nephrectomy: conditional survival analysis.
Abdollah F; Suardi N; Capitanio U; Matloob R; Fossati N; Castiglione F; Di Trapani E; Di Trapani D; Russo A; Carenzi C; Montorsi F; Rigatti P; Bertini R
Urol Oncol; 2014 Jan; 32(1):43.e9-16. PubMed ID: 23911684
[TBL] [Abstract][Full Text] [Related]
35. Oncological outcomes of patients with incidental pathological T3a stage small renal cell carcinoma after partial nephrectomy.
Lee C; You D; Yoo S; Song C; Hong B; Hong JH; Ahn H; Kim CS
J Cancer Res Clin Oncol; 2016 Jul; 142(7):1651-7. PubMed ID: 27193144
[TBL] [Abstract][Full Text] [Related]
36. Pathologic upstaging after laparoscopic radical nephrectomy.
Goel MC; Mohammadi Y; Sethi AS; Brown JA; Sundaram CP
J Endourol; 2008 Oct; 22(10):2257-61. PubMed ID: 18937590
[TBL] [Abstract][Full Text] [Related]
37. Is Robotic Partial Nephrectomy Safe for T3a Renal Cell Carcinoma? Experience of a High-Volume Center.
Andrade HS; Zargar H; Akca O; Kara O; Caputo PA; Ramirez D; Andrés G; Stein RJ; Chueh SJ; Kaouk JH
J Endourol; 2017 Feb; 31(2):153-157. PubMed ID: 27881027
[TBL] [Abstract][Full Text] [Related]
38. Prognostic evaluation of perinephric fat, renal sinus fat, and renal vein invasion for patients with pathological stage T3a clear-cell renal cell carcinoma.
Shah PH; Lyon TD; Lohse CM; Cheville JC; Leibovich BC; Boorjian SA; Thompson RH
BJU Int; 2019 Feb; 123(2):270-276. PubMed ID: 30113768
[TBL] [Abstract][Full Text] [Related]
39. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project).
Brookman-May S; May M; Shariat SF; Xylinas E; Stief C; Zigeuner R; Chromecki T; Burger M; Wieland WF; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Feciche B; Truss M; Gilfrich C; Pahernik S; Hohenfellner M; Zastrow S; Wirth MP; Novara G; Carini M; Minervini A; Simeone C; Antonelli A; Mirone V; Longo N; Simonato A; Carmignani G; Ficarra V;
Eur Urol; 2013 Sep; 64(3):472-7. PubMed ID: 22748912
[TBL] [Abstract][Full Text] [Related]
40. Perioperative morbidity, oncological outcomes and predictors of pT3a upstaging for patients undergoing partial nephrectomy for cT1 tumors.
Mouracade P; Kara O; Dagenais J; Maurice MJ; Nelson RJ; Malkoc E; Kaouk JH
World J Urol; 2017 Sep; 35(9):1425-1433. PubMed ID: 28197727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
